Polymers for reversing heparin-based anticoagulation

• US 9,095,666 B2
• Filed: 12/05/2013
• Issued: 08/04/2015
• Est. Priority Date: 06/01/2011
• Status: Active Grant

• Current Assignee: University of British Columbia
• Original Assignee: University of British Columbia
• Inventors: Kizhakkedathu, Jayachandran N., Shenoi, Rajesh A., Carter, Cedric J., Brooks, Donald E.
• Primary Examiner(s): Barham, Bethany
• Assistant Examiner(s): Cao, Ping
• Application Number:
  US14/098,184
• Publication Number:
  US 20140127312A1
• Time in Patent Office: 607 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 31/795 Polymers containing sulfur
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61M 1/3675 Deactivation
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 2202/0021 removed from and reintroduced into the body, e.g. after treatment
• CPC Class Codes: A61M 2202/0413 Blood
• CPC Class Codes: A61M 2202/0478 Heparin
• CPC Class Codes: B01D 15/36 involving ionic interaction
• CPC Class Codes: C08G 2340/00 Filter material
• CPC Class Codes: C08G 73/024 Polyamines containing oxygen in the form of ether bonds in the main chain
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Claims

1. A method of processing a subject'"'"'s blood, the method comprising:

providing a heparin binding device, the device comprising;

a support; and

a heparin binding polymer immobilized on the support, wherein the heparin binding polymer comprises;

a first dendritic polyol; and

one or more cationic moieties attached to the first dendritic polyol,

wherein the heparin binding polymer comprises at least one of;

a) the structure of Formula (I);

2. The method of claim 1, wherein the subject'"'"'s blood contains heparin.

3. The method of claim 2, wherein the heparin is exogenous heparin.

4. The method of claim 3, wherein the exogenous heparin binds to the heparin binding polymer and is thereby at least partially removed from the subject'"'"'s blood.

5. The method of claim 3, further comprising the step of selecting a heparin binding polymer based upon the type of exogenous heparin administered to the subject.

6. The method of claim 5, wherein a heparin binding polymer of a particular molecular weight is selected based upon the type of exogenous heparin.

7. The method of claim 5, wherein a heparin binding polymer comprising a particular number of cationic groups is selected based upon the type of exogenous heparin.

8. The method of claim 5, wherein the heparin binding polymer works for at least one of:

unfractionated heparin (UFH), low molecular weight heparin (LMWH), ultra low molecular weight heparin (ULMWH), fondaparinux, idraparinux enoxaparin, dalteparin, tinzaparin, semuloparin, or heparinoid.

9. The method of claim 4, wherein returning at least part of the blood to the subject further comprises fortifying the blood with one or more blood constituents that also bind to the heparin binding protein, wherein the fortifying is performed after the blood has contacted the heparin binding polymer.